Tricuspid regurgitation causes: Difference between revisions
Line 9: | Line 9: | ||
===Life Threatening Causes=== | ===Life Threatening Causes=== | ||
Life-threatening causes of TR, which encompass conditions which may result in death or permanent disability within 24 hours if left untreated, include: | Life-threatening causes of TR, which encompass conditions which may result in death or permanent disability within 24 hours if left untreated, include:<ref name="pmid19179197">{{cite journal| author=Shiran A, Sagie A| title=Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management. | journal=J Am Coll Cardiol | year= 2009 | volume= 53 | issue= 5 | pages= 401-8 | pmid=19179197 | doi=10.1016/j.jacc.2008.09.048 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19179197 }}</ref> | ||
*[[graft rejection|Acute cardiac allograft rejection]] | *[[graft rejection|Acute cardiac allograft rejection]] |
Revision as of 23:55, 9 April 2020
Tricuspid Regurgitation Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Tricuspid regurgitation causes On the Web |
American Roentgen Ray Society Images of Tricuspid regurgitation causes |
Risk calculators and risk factors for Tricuspid regurgitation causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2] Fatimo Biobaku M.B.B.S [3]
Overview
Most cases of significant tricuspid regurgitation are due to tricuspid annular dilation and leaflet tethering secondary to right ventricular remodeling from volume and/or pressure overload. Such dilation leads to derangement of the normal anatomy and mechanics of the tricuspid valve and the muscles governing its proper function. The result is incompetence of the tricuspid valve. Common causes of right ventricular dilation include left heart failure, pulmonary hypertension, and right ventricular infarction.
Causes
Life Threatening Causes
Life-threatening causes of TR, which encompass conditions which may result in death or permanent disability within 24 hours if left untreated, include:[1]
- Acute cardiac allograft rejection
- Acute coronary syndrome
- Blunt or penetrating chest trauma
- Infective endocarditis
- Myocardial rupture
- Papillary muscle rupture from ischemic heart disease
- Pulmonary embolism
Common Causes
Common causes of primary tricuspid regurgitation may include:[2][3]
Congenital disease
- Ebstein’s anomaly
- Tricuspid valve dysplasia, hypoplasia, or cleft
- Double orifice tricuspid valve
Acquired disease
- Marantic endocarditis
- Rheumatic disease (with left-sided disease)
- Carcinoid syndrome
- Drug-induced tricuspid regurgitation by using drugs like fenfluramine, phentermine and pergolide[4][5]
- Tricuspid valve prolapse
- Endomyocardial biopsy in cardiac transplant recipients
- Ischemic heart diseases
- Radiation
- Cardiac device (permanent pacemaker, implantable cardioverter-defibrillator) leads
- Trauma
- Right ventricular endomyocardial biopsy
- Blunt chest wall trauma
- Degenerated bioprosthesis
Common causes of secondary tricuspid regurgitation may include:[2]
- Right ventricular and tricuspid annular dilatation
- Left-sided valvular and/or myocardial disease
- Pulmonary hypertension independent of left-sided cardiac pathology
- Right ventricular infarction with remodeling
- Chronic right ventricular pacing (dyssynchrony)
- Atrial fibrillation
Causes by Organ System
Causes in Alphabetical Order
References
- ↑ Shiran A, Sagie A (2009). "Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management". J Am Coll Cardiol. 53 (5): 401–8. doi:10.1016/j.jacc.2008.09.048. PMID 19179197.
- ↑ 2.0 2.1 Rodés-Cabau J, Taramasso M, O'Gara PT (2016). "Diagnosis and treatment of tricuspid valve disease: current and future perspectives". Lancet. 388 (10058): 2431–2442. doi:10.1016/S0140-6736(16)00740-6. PMID 27048553 PMID: 27048553 Check
|pmid=
value (help). - ↑ Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 63 (22): e57–185. doi:10.1016/j.jacc.2014.02.536. PMID pmid24603191 Check
|pmid=
value (help). - ↑ Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB (2004). "Pergolide use in Parkinson disease is associated with cardiac valve regurgitation". Neurology. 63 (2): 301–4. doi:10.1212/01.wnl.0000129842.49926.07. PMID 15277624.
- ↑ 5.0 5.1 Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE (2002). "Valvular heart disease in patients taking pergolide". Mayo Clin Proc. 77 (12): 1280–6. doi:10.4065/77.12.1280. PMID 12479512.
- ↑ 6.0 6.1 6.2 Pereira S, Ganapathy R, Syngelaki A, Maiz N, Nicolaides KH (2011). "Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects". Obstet Gynecol. 117 (6): 1384–91. doi:10.1097/AOG.0b013e31821aa720. PMID 21606749.
- ↑ Kikuchi C, Motohashi S, Takahashi Y, Nakazawa S, Kanazawa H (2013). "A successful treatment for concomitant injury of the coronary artery and tricuspid valve after blunt chest trauma". Gen Thorac Cardiovasc Surg. doi:10.1007/s11748-013-0322-5. PMID 24043608.
- ↑ Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J (2009). "Drug-induced fibrotic valvular heart disease". Lancet. 374 (9689): 577–85. doi:10.1016/S0140-6736(09)60252-X. PMID 19683643.
- ↑ Goyal SB, Aragam JR (2006). "Cardiac sarcoidosis with primary involvement of the tricuspid valve". Cardiol Rev. 14 (5): e12–3. doi:10.1097/01.crd.0000181620.57608.09. PMID 16924157.
- ↑ Malaki M, Ghaffari S, Ghaffari S, Rastkar B, Goldust M, Malaki P; et al. (2011). "Cardiac findings in congenital nephrotic syndrome". J Cardiovasc Thorac Res. 3 (3): 83–5. doi:10.5681/jcvtr.2011.018. PMID 24250960.
- ↑ Cirit M, Ozkahya M, Cinar CS, Ok E, Aydin S, Akçiçek F; et al. (1998). "Disappearance of mitral and tricuspid regurgitation in haemodialysis patients after ultrafiltration". Nephrol Dial Transplant. 13 (2): 389–92. PMID 9509451 PMID 9509451 Check
|pmid=
value (help). - ↑ Acquatella H, Schiller NB, Puigbó JJ, Gómez-Mancebo JR, Suarez C, Acquatella G (1983). "Value of two-dimensional echocardiography in endomyocardial disease with and without eosinophilia. A clinical and pathologic study". Circulation. 67 (6): 1219–26. PMID 6851016.
- ↑ Hendrikx M, Van Dorpe J, Flameng W, Daenen W (1996). "Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature". J Heart Valve Dis. 5 (2): 235–7. PMID 8665020.
- ↑ Wilke A, Hesse H, Hufnagel G, Maisch B (1997). "Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine". Eur Heart J. 18 (4): 701. PMID 9129909.
- ↑ Sagie A, Schwammenthal E, Padial LR, Vazquez de Prada JA, Weyman AE, Levine RA (1994). "Determinants of functional tricuspid regurgitation in incomplete tricuspid valve closure: Doppler color flow study of 109 patients". J Am Coll Cardiol. 24 (2): 446–53. PMID 8034882.
- ↑ Silva-Cardoso J, Moura B, Ferreira A, Martins L, Bravo-Faria D, Mota-Miranda A; et al. (1998). "Predictors of myocardial dysfunction in human immunodeficiency virus-infected patients". J Card Fail. 4 (1): 19–26. PMID 9573500.
- ↑ Paladini D, Tiesi M, Buffi D, Tuo G, Marasini M (2013). "Unexplained right atrial enlargement may be a sign of Holt-Oram syndrome in the fetus". Ultrasound Obstet Gynecol. doi:10.1002/uog.13238. PMID 24185902.
- ↑ Plastiras SC, Economopoulos N, Kelekis NL, Tzelepis GE (2006). "Magnetic resonance imaging of the heart in a patient with hypereosinophilic syndrome". Am J Med. 119 (2): 130–2. doi:10.1016/j.amjmed.2005.10.055. PMID 16443414.
- ↑ Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR (1974). "Cardiac murmurs and endocardial fibrosis associated with methysergide therapy". Am Heart J. 88 (5): 640–55. PMID 4420941.
- ↑ Movahed MR, Saito Y, Ahmadi-Kashani M, Ebrahimi R (2007). "Mitral annulus calcification is associated with valvular and cardiac structural abnormalities". Cardiovasc Ultrasound. 5: 14. doi:10.1186/1476-7120-5-14. PMC 1838405. PMID 17359540.
- ↑ Wilkinson P, Pinto B, Senior JR (1965). "Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis". N Engl J Med. 273 (22): 1178–81. doi:10.1056/NEJM196511252732202. PMID 5847556.
- ↑ Meadows J, Jenkins K (2011). "Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment". Cardiol Young. 21 (4): 363–77. doi:10.1017/S1047951111000102. PMID 21349233.
- ↑ Zheng DW, Shao GF, Feng Q, Ni YM (2013). "Long-term outcome of correction of tetralogy of Fallot in 56 adult patients". Chin Med J (Engl). 126 (19): 3675–9. PMID 24112162.
- ↑ Zosmer N, Bajoria R, Weiner E, Rigby M, Vaughan J, Fisk NM (1994). "Clinical and echographic features of in utero cardiac dysfunction in the recipient twin in twin-twin transfusion syndrome". Br Heart J. 72 (1): 74–9. PMC 1025429. PMID 8068474.